Commentary on Pharmacometrics for Immunotherapy

This commentary provides an overview of recent examples of pharmacometrics applied during the clinical development of two antagonists of the programmed death‐1 (PD‐1) cell surface receptor, pembrolizumab and nivolumab. Despite the remarkable achievements obtained in predicting the correct dosing sch...

Full description

Saved in:
Bibliographic Details
Published in:CPT: pharmacometrics and systems pharmacology 2017-01, Vol.6 (1), p.8-10
Main Authors: Garrido, MJ, Berraondo, P, Trocóniz, IF
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal
Antigens
Antineoplastic Agents
B7-H1 Antigen
Biomarkers
Biomarkers, Tumor
Cytotoxicity
Drug dosages
Humans
Immune system
Immunotherapy
Lung cancer
Lymphocytes
Medical prognosis
Melanoma
Monoclonal antibodies
Neoplasms
Oncology
Pharmacology
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Protein expression
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This commentary provides an overview of recent examples of pharmacometrics applied during the clinical development of two antagonists of the programmed death‐1 (PD‐1) cell surface receptor, pembrolizumab and nivolumab. Despite the remarkable achievements obtained in predicting the correct dosing schedule from different quantitative approaches, data indicated a great degree of heterogeneity in tumor response. To achieve therapeutic goals the search for predictive biomarkers associated with a lack of response and mechanism‐based combination studies are warranted.
ISSN:2163-8306
2163-8306
DOI:10.1002/psp4.12162